Emma Clark

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Sandra M. Swain, José Baselga, Sung‐Bae Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Marion Procter, Evandro de Azambuja et al. · New England Journal of Medicine · 2017 · 1.4K citations · Full text

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Sandra M. Swain, Sung‐Bae Kim, Javier Cortés et al. · The Lancet Oncology · 2013 · 985 citations · Full text

Breast Oncology, Medicine, Cleopatra Study +7

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8